Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event.

MLA

Long, Gerald G., et al. “Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-Dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event.” Toxicologic Pathology, vol. 36, no. 2, Feb. 2008, pp. 218–31. EBSCOhost, https://doi.org/10.1177/0192623307311757.

APA

Long, G. G., Reynolds, V. L., Lopez-Martinez, A., Ryan, T. E., White, S. L., & Eldridge, S. R. (2008). Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event. Toxicologic Pathology, 36(2), 218–231. https://doi.org/10.1177/0192623307311757

Chicago

Long, Gerald G., Vincent L. Reynolds, Alric Lopez-Martinez, Thomas E. Ryan, Sandy L. White, and Sandra R. Eldridge. 2008. “Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-Dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event.” Toxicologic Pathology 36 (2): 218–31. doi:10.1177/0192623307311757.